LEADER 01638nam  2200421Ia 450 
001 9910698879303321
005 20090507150235.0
035   $a(CKB)5470000002397070
035   $a(OCoLC)320464613
035   $a(EXLCZ)995470000002397070
100   $a20090507d2007      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $e"lookback" for hepatitis c virus (HCV) : product quarantine, consignee notification, further testing, product disposition, and notification of transfusion recipients based on donor test results indicating infection with HCV
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER),$d[2007]
215   $ai, 18 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 7, 2009).
300   $a"August 2007".
320   $aIncludes bibliographical references (page 8).
517   $aGuidance for industry 
606   $aHepatitis C virus
606   $aBlood$xTransfusion$zUnited States
606   $aBlood donors$zUnited States
606   $aBloodborne infections$zUnited States
615  0$aHepatitis C virus.
615  0$aBlood$xTransfusion
615  0$aBlood donors
615  0$aBloodborne infections
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698879303321
996   $aGuidance for industry$93434577
997   $aUNINA